The DOI matches its Crossref record; 505 of the 505 references it cites were found in a registry or an index.
Diabetic kidney disease
Open accessAbstract
The kidney is arguably the most important target of microvascular damage in diabetes. A substantial proportion of individuals with diabetes will develop kidney disease owing to their disease and/or other co-morbidity, including hypertension and ageing-related nephron loss. The presence and severity of chronic kidney disease (CKD) identify individuals who are at increased risk of adverse health outcomes and premature mortality. Consequently, preventing and managing CKD in patients with diabetes is now a key aim of their overall management. Intensive management of patients with diabetes includes controlling blood glucose levels and blood pressure as well as blockade of the renin–angiotensin–aldosterone system; these approaches will reduce the incidence of diabetic kidney disease and slow its progression. Indeed, the major decline in the incidence of diabetic kidney disease (DKD) over the past 30 years and improved patient prognosis are largely attributable to improved diabetes care. However, there remains an unmet need for innovative treatment strategies to prevent, arrest, treat and reverse DKD. In this Primer, we summarize what is now known about the molecular pathogenesis of CKD in patients with diabetes and the key pathways and targets implicated in its progression. In addition, we discuss the current evidence for the prevention and management of DKD as well as the many controversies. Finally, we explore the opportunities to develop new interventions through urgently needed investment in dedicated and focused research. For an illustrated summary of this Primer, visit: http://go.nature.com/NKHDzg
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Nakao, N., Yoshimura, A., Morita, H., Takada, M., Kayano, T., & Ideura, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12229-5 · Cited by 970
RetractedChobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
Self-citationStandards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Cited by
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Thomas, M. C., Cooper, M. E., & Zimmet, P. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.173 · Cited by 742
Self-citationDiabetic vascular diseases: molecular mechanisms and therapeutic strategies
Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01400-z · Cited by 704
The Global Epidemiology of Diabetes and Kidney Disease
Koye, D. N., Magliano, D. J., Nelson, R. G., & Pavkov, M. E. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.10.011 · Cited by 686
Antar, S. A., Ashour, N. A., Sharaky, M., Khattab, M., Ashour, N. A., Zaid, R. T., Roh, E. J., Elkamhawy, A., & Al-Karmalawy, A. A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115734 · Cited by 622
The tubular hypothesis of nephron filtration and diabetic kidney disease
Vallon, V., & Thomson, S. C. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0256-y · Cited by 465
The cardio-renal-metabolic connection: a review of the evidence
Marassi, M., & Fadini, G. P. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01937-x · Cited by 386
Tang, G., Li, S., Zhang, C., Chen, H., Wang, N., & Feng, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.12.020 · Cited by 364
Molecular pathways that drive diabetic kidney disease
Mohandes, S., Doke, T., Hu, H., Mukhi, D., Dhillon, P., & Susztak, K. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165654 · Cited by 341
Self-citationSodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology
Ferrannini, E. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.011 · Cited by 340
Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy
Rayego-Mateos, S., Morgado-Pascual, J. L., Opazo-Ríos, L., Guerrero-Hue, M., García-Caballero, C., Vázquez-Carballo, C., Mas, S., Sanz, A. B., Herencia, C., Mezzano, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113798 · Cited by 334
Młynarska, E., Czarnik, W., Dzieża, N., Jędraszak, W., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., & Franczyk, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031094 · Cited by 328
Network biology concepts in complex disease comorbidities
Hu, J. X., Thomas, C. E., & Brunak, S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.87 · Cited by 328
Inter-organ crosstalk during development and progression of type 2 diabetes mellitus
Xourafa, G., Korbmacher, M., & Roden, M. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00898-1 · Cited by 274
Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease
Jung, C.-Y., & Yoo, T.-H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0329 · Cited by 262
Cortinovis, M., Perico, N., Ruggenenti, P., Remuzzi, A., & Remuzzi, G. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00559-y · Cited by 214
New progress in drugs treatment of diabetic kidney disease
Wang, J., Xiang, H., Lu, Y., Wu, T., & Ji, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111918 · Cited by 74
Siddiqui, K., George, T. P., Joy, S. S., & Alfadda, A. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1079725 · Cited by 59
The clustering of Cardiovascular, Renal, Adipo-Metabolic Eye and Liver disease with type 2 diabetes
Thomas, M. C. (2022) · Metabolism · doi:10.1016/j.metabol.2021.154961 · Cited by 41
Self-citationKristensen, F. P. B., Sanchez-Lastra, M. A., Dalene, K. E., del Pozo Cruz, B., Ried-Larsen, M., Thomsen, R. W., Ding, D., Ekelund, U., & Tarp, J. (2023) · Diabetes Care · doi:10.2337/dc23-0937 · Cited by 29
Machine Learning for Predicting the 3-Year Risk of Incident Diabetes in Chinese Adults
Wu, Y., Hu, H., Cai, J., Chen, R., Zuo, X., Cheng, H., & Yan, D. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.626331 · Cited by 28
Li, Y., Jin, N., Zhan, Q., Huang, Y., Sun, A., Yin, F., Li, Z., Hu, J., & Liu, Z. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1495306 · Cited by 35
“These discrepancies may affect the prediction accuracy and stability of the models (6).”
Fauchier, L., Boriani, G., de Groot, J. R., Kreutz, R., Rossing, P., & Camm, A. J. (2021) · EP Europace · doi:10.1093/europace/euab184 · Cited by 22
Self-citationHealthy and unhealthy aging on kidney structure and function: human studies
Denic, A., Rule, A. D., & Glassock, R. J. (2022) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000780 · Cited by 20
Yang, C., Zhang, H., Ma, Z., Fan, Y., Xu, Y., Tan, J., Tian, J., Cao, J., Zhang, W., Huang, G., et al. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.70029 · Cited by 11
Metadata
- Authors
- Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E.
- Venue
- Nature Reviews Disease Primers
- Published
- 2015-07-30
- Volume
- 1
- Issue
- 1
- Pages
- 15018-15018
- ISSN
- 2056-676X (ISSN-L)
- OpenAlex
- W2394782024
- Cited by
- 1,230
- References
- 505
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.